CrownBio Enhances Its European Capabilities with New Generation of Innovative Translational Models for Obesity and Diabetes
SANTA CLARA, Calif., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the availability of their proprietary FATZO(TM) model in a European based laboratory. The establishment of this improved translational model provides the European scientific community with unfettered access to an advanced research tool for use in preclinical studies of obesity, dysmetabolism and type 2 diabetes.
The FATZO(TM) is a next generation preclinical research model for obesity, metabolic disorders, diabetes and related complications. The unique feature of an intact leptin system enables the FATZO model to provide novel scientific insights into the physiological and cellular mechanisms that lead from obesity / metabolic disorders to diabetes. It examines polygenic causes of obesity and mimics human pathophysiology by exhibiting metabolic patterns of hyperglycemia and hyperinsulinemia.
"Obesity and diabetes have a significant global impact, affecting more than 422 million people worldwide. We expanded our FATZO(TM) model to ensure European researchers have ready access to the best translational tools available to advance the drug development programs aimed at curing these diseases," said Jim Wang, M.D., Crown Bioscience's Senior Vice President Cardiovascular and Metabolic Diseases (CVMD) Research.
"The establishment of our FATZO(TM) model in Europe is pivotal to Crown Bioscience's commitment to providing translational models that are representative of human conditions of obesity, type 2 diabetes and related comorbidities," said Jean-Pierre Wery, Ph.D., CEO of Crown Bioscience. "We look forward to working with European scientists to help answer their most challenging questions about these diseases and enable more effective drug discovery for their treatment."
For more information on CrownBio's commitment to advance the field of cardiovascular and metabolic drug discovery, visit https://www.crownbio.com/cvmd.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc. email@example.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Barings Supports New Mountain Capital Investment in DRB Systems17.10.2017 16:30 | Pressmeddelande
CHARLOTTE, N.C., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as a Joint Lead Arranger on a Senior Secured Credit Facility to support New Mountain Capital's acquisition of DRB Systems LLC. Founded in 1984 and based in Akron, Ohio, DRB Systems is the leading provider of turnkey technology solutions used to enhance the operational efficiency of car wash sites across the U.S. DRB's integrated technology offering includes hardware and software used in point-of-sale and tunnel control systems as well as ancillary modules to support marketing, human resources, and business analytics. "New Mountain Capital is pleased to have completed its investment in DRB Systems," said Jack Qian, Director of New Mountain Capital. Laura Holson, Head of Capital Markets at New Mountain added, "We deeply value Barings' support as a financing pa
Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds17.10.2017 16:12 | Pressmeddelande
SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year's American Association for Cancer Research's International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) October 26th through the 30th. CrownBio's scientists will present 13 scientific posters describing their latest research efforts, including generation of novel models for combinatory chemotherapy and immunotherapy studies, creation of 3D screening panels for improved efficacy assessments, demonstration of a checkpoint immunotherapy modulating intestinal microbiota, among other innovative developments in cancer therapeutics and preclinical pharmacology evaluation. On
Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 201717.10.2017 15:15 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release third quarter 2017 financial results prior to market open on Tuesday, October 31, 2017. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 99539511, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations se
World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions17.10.2017 08:16 | Pressmeddelande
YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today's press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) featured groundbreaking findings in the study of both small cell and non-small cell lung cancer. The studies presented covered broad research areas, from confirmation of existing classification criteria to ensuring viability of evidence to supporting the use of specific interventions. Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. These results may lead to further evaluation of the scoring system for predicting DLL3-targeted therapeutic efficacy and clinical significance of DLL3 expression in high-grade pulmonary neuroendocrine carcinomas.
New Era Launches Direct-to-Consumer eCommerce Site Built by EPAM and Powered with SAP Hybris17.10.2017 06:01 | Pressmeddelande
New Site Expands Headwear and Apparel Offering with Immersive, Omnichannel Experience NEWTOWN, Pa., Oct. 17, 2017 (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development services, and New Era, a global headwear brand rooted in sports, today announced the launch of New Era's first direct-to-consumer website, neweracap.com. New Era's B2B business remains strong, and the company is now putting an emphasis on selling its products directly to customers and expanding its offering into the lifestyle market. The new site offers products for seasoned athletes and sports fans, as well as street and lifestyle consumers. "In an age where businesses cannot tolerate lengthy, scope changing technology projects, EPAM quickly established themselves as the standout partner for us to tackle this ambitious initiative," said Lorenz Gan, Global Vice President, Information Technology, New Era. "Whilst this p
CP Kelco Appoints Didier Viala as New President16.10.2017 15:00 | Pressmeddelande
ATLANTA, Oct. 16, 2017 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that Didier Viala has been appointed President, effective October 1, 2017. Viala replaces Donald Rubright, who served as CP Kelco President since 2006 and will retire at the end of 2017. Viala has also joined the CP Kelco Board of Directors. "As a market leader supplying high-quality hydrocolloid products for a range of foods and beverages, consumer products and industrial applications, CP Kelco will continue to invest in capacity additions, new product and applications development, strategic raw material sourcing, quality and safety management, and sustainability initiatives to support our customers' innovation efforts and growth strategies," Viala said. Over the course of more than 25 years with CP Kelco and its predecessor companies, Viala held leadership roles across a broad spectrum of critical areas, including innovat
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum